NASDAQ: STXS

Exhibit 99.2

Forward-Looking Statements

During the course of this presentation, the Company may make projections and other forward-

looking statements regarding future events or the future financial performance of the Company,

including without limitation, statements regarding future operating results, growth opportunities

and

other

statements

that

refer

to

Stereotaxis’

plans,

prospects,

expectations,

strategies,

intentions and beliefs. These statements are subject to many risks and uncertainties that could

cause actual results to differ materially from expectations.

For a detailed discussion of risk and uncertainties that affect the Company’s business and qualify

the forward-looking statements made in this presentation, we refer you to the Company’s recent

public filings filed with the SEC, specifically the Form 10-K for the fiscal year ended December

31, 2009.

The Company’s projections and forward-looking statements are based on factors that are subject

to change and therefore these statements speak only as of the date they are given. The

Company assumes no obligation to update any projections or forward-looking statements.

In addition, regarding orders and backlog, there can be no assurance that the Company will

recognize revenue related to its purchase orders and other commitments in any particular period,

or at all, because some of these purchase orders and other commitments are subject to

contingencies that are outside of our control. These orders and commitments may be revised,

modified,

or

canceled

either

by

their

express

terms,

as

a

result

of

negotiations,

or

by

project

changes or delays.

2

Investment Considerations

Addressing market opportunity through two distinct

platforms:

Magnetic Navigation (Niobe)

Enterprise Solutions (Odyssey)

Large, high growth (+20%) cardiology ablation market

Commercial ramp began in mid 2008; leading peer

group grower in 2009 through strong fundamentals

Poised for continued growth in EP

Long term platform expansion into new markets

3

Stereotaxis

–

Magnetic Platform

Stereotaxis

steers the catheter’s distal tip through external magnetic fields thus

giving the physician precise remote control of therapeutic devices.

4

Stereotaxis

Value –

Magnetic Platform

Precise control of the distal tip of the catheter results in:

Exemplary safety

Effective lesion creation through

constant contact

Exceptional mapping capability 

Proven in all chambers of the heart

5

Before Stereotaxis

After Stereotaxis

Physician

Efficacy

Safety

Efficiency

In procedure room

Physician:

significant X-ray exposure

Patient:

major event rate ~2.8%

Wide standard deviation based on

patient and physician

In control room

Several applications clearly better than manual

-

VT, pediatrics, congenital heart diseases

Other applications comparable to manual

Almost no X-ray exposure

Major event rate reduced to 0.1%

Standardized process drives tighter distribution

around procedure times

High re-do rates

Clinical Environment Overview Market

6

Global EP Market

Source: Millennium Research Group (2009); Stereotaxis internal analysis

EP Procedures

Routine

AF

VT

Other

Total

Complex

Prevalence

Annual Procedures

Annual Growth

+20M

+10M

+3M

+5M

+18M

170k

100k

30k

40k

170k

<10%

25%

15%

15%

20%

Our

Focus

7

Strong

Clinical Validation

More than 150 Peer-Reviewed

Publications

Atrial

Fibrillation

30 Publications

Up

to

100%

acute

success

Improved

chronic

outcomes

Pediatric Arrhythmia

5 publications

93% acute success

Low fluoro, no complications

Congenital Heart

6 publications

90%

success

rate

“As easy as normal adults”

Ventricular Tachycardia

13 publications

Up

to

100%

acute

success

85%

freedom

at

1

year

Radiation Reduction

Patients

–

67%

Physicians

–

90%

1. Haghjoo,  JCE 2009.  2. Latcu, Arch Cardiovasc

Dis

2009.  3. Schwagten, PACE 2009.  4. DiBiase, JCE 2009.

5. Augello, Heart Rhythm 2009. 6. Schwagten, PACE 2009. 7. Haghjoo, JCE 2009.  8. Dibiase, Heart Rhythm 2009.

8

3

6

4

5

7

8

2

1

VT Comparison Study Erasmus MC

•

64 consecutive VT ablation patients

–

37 Stereotaxis

–

27 manual

–

Idiopathic & Scar-Related

•

No complications in Stereotaxis

group

•

1 tamponade/death in manual group

•

Conclusion: “Major

clinical & cost advantages for VT ablation”

97%

14%

170

25

8

81%

50%

228

57

13

0

50

100

150

200

250

Acute Success (%)

Recurrence (%)

Case Time (min)

Fluoro Time (min)

RF Apps

STXS

Manual

p

= 0.03

p

< 0.01

p

< 0.01

p

< 0.001

NS

9

Schwagten, et al. Eur Heart J 2010, 31(Supp):932.

Odyssey Enterprise

TM

Solutions

Odyssey Vision

10

The Odyssey Product Line

CONNECT

CINEMA

VISION

Efficiently integrate

data and control

during procedures

Standardize all labs

to increase staff

effectiveness

Drive world-class

practices by capturing,

compressing and

recording data for storage

and networking

NIOBE

Accelerate clinical

education by playing back

synchronized lab data

Drive quality of patient

care by connecting

clinical experts

Build market exposure

through live web events

showcasing clinical

capabilities

Enhance clinical

capabilities with a

robotic suite

15,000 Interventional

Standard Labs

140 Niobe

Labs

$10K / Year

$190K List

$225K -

$360K List

11

Business Model

Capital Revenue

Recurring Revenue

Niobe

Odyssey

Workstation

Odyssey

Cinema

•

141 Niobe

systems installed

•

2,500 EP labs worldwide

•

20+% growth; ~60% margin

•

25% growth (YTD 2010 vs. 2009)

•

80% margin

Equipment service

•

Technical service

•

Software license

•

1-year warranty

Niobe

Utilization

•

Stereotaxis

disposables

•

Royalty from J&J BWI

27% growth (2009 vs. 2008); 65+% margin

12

Market Adoption & Procedure Growth

Growing Worldwide Penetration

141 Systems Installed

60% US -

40% OUS

Canada -

3

United States -

77

Europe -

49

Saudi Arabia -

1

Russia -

1

China -

5

Korea -

1

Japan -

1

Singapore -

1

Taiwan -

1

Australia -

1

13

$0.0

$4.0

$8.0

$12.0

$16.0

Q1

Q2

Q3

Q4

2008

2009

2010

$11.2

$8.8

$7.2

$7.3

$5.0

$10.2

$12.4

$6.3

$11.2

$7.7

New Orders to Backlog

Revenue Momentum

Recurring Revenue

$ millions

$ millions

$0

$2

$4

$6

$8

$10

$12

$14

$16

Q1

Q2

Q3

Q4

2008

2009

2010

$7.0

$11.1

$10.6

$10.7

$12.6

$15.0

$10.6

$13.3

$12.1

$14.1

$ millions

Stereotaxis

Financial Update

14

$0.0

$4.0

$8.0

$12.0

Q1

Q2

Q3

Q4

2008

2009

2010

Total Inventory

-$20.0

-$15.0

-$10.0

-$5.0

$0.0

$5.0

Q1

Q2

Q3

Q4

Cash Flow (Burn)

$0.0

$5.0

$10.0

$15.0

$20.0

$25.0

Q1

Q2

Q3

Q4

2008

2009

2010

Operating Expenses

55.0%

60.0%

65.0%

70.0%

75.0%

Q1

Q2

Q3

Q4

2008

2009

2010

Gross Margin Percentage

$ millions

$ millions

$ millions

65.5%

68.9%

72.5%

60.8%

63.1%

65.5%

67.8%

67.6%

67.3%

$17.8

$14.8

$14.0

$18.7

$14.6

$16.1

$13.3

$14.6

$15.3

-$12.6

-$11.4

-$6.4

-$7.6

-$5.8

-$3.5

-$4.5

-$2.9

$10.5

$8.1

$4.9

$9.6

$7.5

$8.4

$7.0

$8.1

$4.4

67.2%

$15.8

$4.3

Stereotaxis

Financial Update

15

-$7.9

-$5.6

2008

2009

2010

Liquidity

$3.0

$1.3

$3.6

$0

$2

$4

$6

$8

$10

2010

Operating Cash Flow Ex A/R

BWI Debt

Accounts Receivable

Q2 2010 Cash Burn Analysis

$ Millions

$7.9

$ Millions

$26.3

$19.4

* Cash burn includes repayment of Biosense

Webster advance.

*

16

$6.6

$12.8

$4.3

$30.3

$23.8

$20.7

$22.0

$0

$5

$10

$15

$20

$25

$30

$35

Cash Burn

Cash

Credit Line Availabilty

2008

2009

TTM June

30, 2010

June 30,

2010

June 30,

2009

2010 Focus

I.

Drive Commercial Success

Clinical training/process accelerates adoption

Adoption

creates

stronger

reference

sites

Reference

sites

accelerate

capital

pipeline

&

sales

Niobe

orders generate Odyssey opportunities

Odyssey

(robotic

labs)

placements

generate

standard

lab interest

II.Strengthen EP Product Offering

Product

extensions

Odyssey

link,

Interface,

Carto

III

New

capabilities

launched

with

VDrive™

* Year to Date 2010

17

Metrics

25% growth recurring revenue*

5

17

Q2 2010 orders doubled over 2009

Odyssey revenue up 164%*

Standard lab sales 36% of total

Odyssey*

Q & A

18